Treatment of Metastatic Colorectal Cancer With or Without Bevacizumab: Can the Neutrophil/Lymphocyte Ratio Predict the Efficiency of Bevacizumab? |
Dirican, Ahmet
(Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital)
Varol, Umut (Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) Kucukzeybek, Yuksel (Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) Alacacioglu, Ahmet (Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) Erten, Cigdem (Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) Somali, Isil (Department of Medical Oncology, Institute of Oncology, Dokuz Eylul University) Can, Alper (Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) Demir, Lutfiye (Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) Bayoglu, Ibrahim Vedat (Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) Akyol, Murat (Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) Yildiz, Yasar (Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) Koyuncu, Betul (Department of Internal Medicine, Izmir Katip Celebi University Ataturk Training and Research Hospital) Coban, Eyup (Department of Internal Medicine, Izmir Katip Celebi University Ataturk Training and Research Hospital) Tarhan, Mustafa Oktay (Department of Medical Oncology, Institute of Oncology, Dokuz Eylul University) |
1 | Saltz LB, Clarke S, Diaz-Rubio E, et al (2008). Bevacizumab in combination with oxaliplatin-based chemotherapy as firstline therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol, 26, 2013-9 DOI ScienceOn |
2 | Stathopoulos GP, Batziou C, Trafalis D, et al (2010). Treatment of colorectal cancer with and without bevacizumab: a phase III study. Oncology, 78, 376-81. DOI |
3 | Unal D, Eroglu C, Kurtul N, Oguz A, Tasdemir A (2013). Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis? Asian Pac J Cancer Prev, 14, 5237-42. 과학기술학회마을 DOI ScienceOn |
4 | Uygun K, Bilici A, Kaya S, et al (2013). XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions. Asian Pac J Cancer Prev, 14, 2283-8. 과학기술학회마을 DOI ScienceOn |
5 | Van Cutsem E, Rivera F, Berry S, et al (2009). First BEAT investigators. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol, 20, 1842-7. DOI ScienceOn |
6 | Wang S, Zhang Z, Fang F, et al (2011). The neutrophil/lymphocyte ratio is an independent prognostic indicator in patients with bone metastasis. Oncol Lett, 2, 735-740. DOI |
7 | Zheng YB, Zhao W, Liu B, et al (2013). The blood neutrophil-tolymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib. Asian Pac J Cancer Prev, 14, 5527-31. 과학기술학회마을 DOI ScienceOn |
8 | Macedo LT, da Costa Lima AB, Sasse AD, et al (2012). Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups. BMC Cancer, 13, 89. |
9 | Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol, 23, 3697-705. |
10 | Kacan T, Babacan NA, Seker M, et al (2014). Could the neutrophil to lymphocyte ratio be a poor prognostic factor for non small cell lung cancers? Asian Pac J Cancer Prev, 15, 2089-94. 과학기술학회마을 DOI |
11 | Kemal Y, Yucel I, Ekiz K, et al (2014). Elevated serum neutrophil to lymphocyte and platelet to lymphocyte ratios could be useful in lung cancer diagnosis. Asian Pac J Cancer Prev, 15, 2651-4. 과학기술학회마을 DOI ScienceOn |
12 | Ozdemir Y, Akin ML, Sucullu I, Balta AZ, Yucel E (2014). Pretreatment neutrophil/lymphocyte ratio as a prognostic aid in colorectal cancer. Asian Pac J Cancer Prev, 15, 2647-50. 과학기술학회마을 DOI ScienceOn |
13 | Pectasides D, Papaxoinis G, Kalogeras KT, et al (2012). XELIRIbevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis. BMC Cancer, 12, 271. DOI |
14 | Giantonio BJ, Catalano PJ, Meropol NJ, et al (2007). Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol, 25, 1539-44. DOI ScienceOn |
15 | Proctor MJ, McMillan DC, Morrison DS, et al (2012). A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer, 107, 695-9. DOI |
16 | Gyanchandani R, Sano D, Ortega Alves MV, et al (2013). Interleukin-8 as a modulator of response to bevacizumab in preclinical models of head and neck squamous cell carcinoma. Oral Oncol, 49, 761-70. DOI |
17 | Fuchs CS, Marshall J, Barrueco J, et al (2008). Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol, 26, 689-90. DOI ScienceOn |
18 | Gunduz S, Mutlu H, Uysal M, Coskun HS, Bozcuk H (2014). Prognostic value of hematologic parameters in patients with metastatic renal cell carcinoma using tyrosine kinase inhibitors. Asian Pac J Cancer Prev, 15, 3801-4. 과학기술학회마을 DOI |
19 | Hurwitz HI, Fehrenbacher L, Novotny W, et al (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med, 350, 2335-42. DOI ScienceOn |
20 | Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al (2005). Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol, 23, 3502-8 DOI ScienceOn |
21 | Cedres S, Torrejon D, Martinez A, et al (2012). Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clin Transl Oncol, 14, 864-9. DOI ScienceOn |
22 | Hochster HS, Hart LL, Ramanathan RK, et al (2008). Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol, 26, 3523-9. DOI ScienceOn |
23 | Ishizuka M, Nagata H, Takagi K, et al (2012). Clinical significance of tumor pathology for postoperative survival of patients undergoing surgery for stage IV colorectal cancer. Anticancer Res, 32, 3291-7. |
24 | De Gramont A, Figer A, Seymour M, et al (2000). Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol, 18, 2938-47. DOI |
25 | Cihan YB, Ozturk A, Mutlu H (2014). Relationship between prognosis and neutrophil: lymphocyte and platelet:lymphocyte ratios in patients with malignant pleural mesotheliomas. Asian Pac J Cancer Prev, 15, 2061-7. 과학기술학회마을 DOI |
26 | Ducreux J, Bennouna M, Hebbar M, et al (2007). Efficacy and safety findings from a randomized phase III study of capecitabine and oxaliplatin vs infusion 5-FU/LV+O (FOLFOX-6) for metastatic colorectal cancer (MCRC) (abstract). J Clin Oncol, 25, 170. |
27 | Eisenhauer EA, Therasse P, Bogaerts J, et al (2009).New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer, 45, 228-47. DOI ScienceOn |
28 | Ferrara N, Kerbel RS (2005). Angiogenesis as a therapeutic target. Nature, 438, 967-74. DOI ScienceOn |
29 | Abajo A, Boni V, Lopez I, et al (2012). Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients. Br J Cancer, 107, 287-90. DOI |
30 | Formica V, Massara MC, Portarena I, et al (2009). Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients. Cancer Biomark, 5, 167-75. DOI |
31 | Algire GH, Chalkley HW, Legallais FY, Park HD (1945). Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J Natl Cancer Inst, 6, 73-85. DOI |
32 | Botta C, Barbieri V, Ciliberto D, et al (2013). Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. Cancer Biol Ther, 14, 469-75. DOI |
33 | Clarke S, Burge M, Cordwell C, et al (2013). An Australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab . BMC Cancer, 13, 120. DOI |
34 | Price TJ, Zannino D, Wilson K, et al (2012). Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of capecitabine, bevacizumab and mitomycin C. Ann Oncol, 23, 1531-6. DOI |
35 | Fuchs CS, Marshall J, Mitchell E, et al (2007). Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol, 25, 4779-86. DOI ScienceOn |